Cytovation
Developing CyPep-1, the first synthetic peptide engineered to selectively target tumor cell membranes based on their altered molecular composition.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 Valuation: €0.0 | round | |
* | $6.0m Valuation: $100m | Early VC | |
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Cytovation ASA is a biotechnology company specializing in the development of novel immunotherapies aimed at treating various types of cancer. Leveraging over 15 years of research from the University of Bergen and Haukeland University Hospital, Cytovation focuses on engineering highly stable synthetic peptides with unique antitumoral properties. The company's lead candidate, CyPep-1, is designed to stimulate the immune system to recognize and eradicate tumors through a dual mode of action. Cytovation primarily serves patients with cancer, operating within the oncology market. The business model revolves around the development and commercialization of innovative cancer treatments, generating revenue through partnerships, licensing agreements, and eventual product sales.
Keywords: biotechnology, immunotherapy, cancer treatment, synthetic peptides, CyPep-1, tumor eradication, oncology, research-driven, dual action, peptide engineering.